Christopher H. Cabell
President, Head of Research & Development and Chief Medical OfficerDr. Christopher H. Cabell, also known as Chris, M.D., MHS, FACC, M.H.Sc, serves as President and Head of Research & Development at Inhibikase Therapeutics, Inc. since February 2025 and serves as Chief Medical Officer since March 2025. Dr. Cabell was Chief Executive Officer at CorHepta Pharmaceuticals, which was acquired by Inhibikase. He served as Director at ScienceMedia, Inc. since February 2020. He served as a Senior Vice President and Head of Clinical Development at Emergent BioSolutions Inc. since February 2021 until 2022. He is an Advisor to Arena Pharmaceuticals, Inc. Dr. Cabell had been Executive Vice President and Head of Research and Development at Arena Pharmaceuticals, Inc. since June 9, 2020 until December 01, 2020 and also served as its Chief Medical Officer since 2019 until December 01, 2020. He served as Chief Medical Officer and Executive Vice President at Zura Bio Limited since January 2023 until January 15, 2024 and served as its Head of R&D until January 15, 2024. Dr. Cabell has been Independent Director of Pulmatrix, Inc. since June 23, 2020. He served as Senior Vice President at Arena Pharmaceuticals, Inc from October 2017 until June 9, 2020. Dr. Cabell had been Head of Clinical Development at Arena Pharmaceutical, Inc. since October 2017 until 2019. He served as Chief Medical Officer of IQVIA. Dr. Cabell served as Senior Vice President of Therapeutic & Specialty Business Development at Quintiles Transnational Corp. Dr. Cabell had been Senior Vice President of Therapeutic & Specialty Business Development at IQVIA Holdings Inc. since October 21, 2015. He serves as Senior Vice President and Head of the Therapeutic & Specialty Business Development team within the Customer Solutions Management Group (CSMG). With oversight of regional and functional clinical development sales and the Therapeutic Centers of Excellence, he is responsible for leveraging CSMG's deep therapeutic expertise across all of CSMG's core customer segments to strengthen its selling approach and engage its customers in the sales process. Dr. Cabell served as an Executive Officer of Medical and Scientific Services Group of Global Clinical Development Services at Quintiles Transnational Corp. and was responsible for serving as a Medical Advisor on clinical project teams and providing support to investigative sites and project staff regarding protocol issues. Prior to assuming this role in November 2014, he served as Head of the Therapeutic Delivery Unit for Quintiles, responsible for developing clinical and business strategies to deliver Phase II-III clinical trials evaluating vaccines, drugs and therapies targeting hundreds of diseases. He joined Quintiles in 2007 as the cardiovascular/endocrine global therapeutic group leader and has held numerous roles. He is a technology veteran with many years of software development experience. Dr. Cabell served as Chief Scientific Officer and Chief Medical Officer of Quintiles Transnational Corp. from June 2008 to August 2011. Previously, Dr. Cabell spent 10 years at Quintiles Inc. and QuintilesIMS in a variety of management positions including Global Head of Medical and Project Management and Global Head of Business Development from October 2007 to September 2017. He served with Duke University School of Medicine, where he developed a strong background in cardiac safety. Dr. Cabell served as Co- Chair and Principal Investigator of a Duke/FDA Cardiac Safety partnership of the Duke Clinical Research Institute (DCRI), to develop a new generation of tools to identify the potential effects of medical devices and drugs on the heart. He served as Director of the Echocardiography Core Laboratory, Associate Director of the ECG Core Laboratory and Director of the International Collaboration on Endocarditis of Duke Clinical Research Institute (DCRI). Dr. Cabell served as an Assistant Professor of Medicine in the Division of Cardiology. He authored or Co-Authored 50 articles for peer-reviewed publications and delivered more than 30 invited lectures. Dr. Cabell is an Expert Cardiologist and Clinical Investigator. He is a Member of several professional organizations and a reviewer for a number of medical journals, including the Journal of the American Medical Association. Dr. Cabell is a Fellow of the American College of Cardiology and has over 100 peer reviewed publications including in the New England Journal of Medicine, JAMA and Annals of Internal Medicine. Dr. Cabell earned his Medical Degree and a Master's in Health Science from the Duke University School of Medicine. He is an honors graduate of The Pennsylvania State University and received MD and MHS degree from Duke University School of Medicine from 1990 to 1994.
Positions
- Company NameInhibikase Therapeutics, Inc.Stock CodeIKTPositionPresident, Head of Research & Development and Chief Medical OfficerColleagues
- MTMark T. IwickiCEO & Director
- ADAmit D. MunshiIndependent Chairman
- DJDavid John McIntyreChief Financial Officer
- JAJohn AdamsChief Scientific Officer
- JJJeffrey J. KagyChief Human Resources Officer
- AKArvind KushIndependent Director
- RFRoberto Francesco BelliniIndependent Director
- TMTed M. DawsonMember of Scientific Advisory Board
